The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1): “CSL Behring is pleased to inform you that we are lifting our precautionary distribution hold, and ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] is now available forContinue Reading

FLINT, Mich., Aug. 8, 2019 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office and in-home delivery and administration of infusion drugs and biologics. The agreement will cover treatments for primary immunodeficiency, alpha-1 antitrypsin deficiency, hereditary angioedema, and more. Allergy PartnersContinue Reading

The Alpha-1 Foundation was informed by CSL Behring that a Voluntary Biological Product Recall is being initiated for 4 lots of Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). According to CSL Behring, these lots are being voluntarily recalled as a precautionary measureContinue Reading